Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.55 |
| ▸ | MAOA | P21397 | 16/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471642 | 0.97 | MAOB (0.55) | MAOBMAOAPRKCIGRM5HSD17B1 | |
| SCHEMBL3988527 | 0.92 | MAOB (0.64) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL4157926 | 0.91 | MAOB (0.57) | MAOBMAOAGRM5HSD17B1 | |
| SCHEMBL1513290 | 0.90 | MAOA (0.53) | MAOBMAOA | |
| SCHEMBL8520563 | 0.86 | MAOA (0.50) | MAOBMAOA | |
| SCHEMBL8520565 | 0.86 | MAOA (0.50) | MAOBMAOA | |
| SCHEMBL17332072 | 0.83 | MAOB (0.42) | MAOBMAOA | |
| SCHEMBL4427945 | 0.82 | STS (0.59) | — | |
| SCHEMBL3821515 | 0.81 | MAOB (0.55) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL29758928 | 0.81 | MAOB (0.58) | MAOBMAOAPRKCIHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658638-A1 | SMALL MOLECULES FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2025-12-10 | — | — | EP | disclosed |
| CN-118546142-A | Novel quinazoline and tetrahydronaphthalene ring PROTAC compound and preparation method and application thereof | 辽宁大学 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024161423-A1 | SMALL MOLECULES FOR THE TREATMENT OF MYCOBACTERIAL DISEASES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024125464-A1 | TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116023383-A | Synthesis method of chiral tetrahydrofurano [2,3-b ] tetrahydroquinoline derivative | 广西师范大学 | 2023-04-28 | — | — | CN | disclosed |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-0721942-B1 | TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO KK (JP) | 2002-06-05 | — | — | EP | disclosed |
| CN-1282243-A | Pharmaceutical composition containing anilide derivative for antagonizing CCR5 | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
| US-6110910-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTIRHEUMATIC AGENTS, ANTICARCINOGENIC AGENTS | DUPONT PHARMACEUTICALS (US) | 2000-08-29 | — | — | US | disclosed |
| US-5874441-A | TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| US-5646283-A | IMMUNOSUPPRESSANTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5639759-A | ORGAN TRANSPLANTATION; AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTIARTHRITIC AGENTS; ANTICANCER AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0721942-A1 | NOVEL TETRACYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0716652-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5428040-A | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995006640-A1 | CARBOCYCLIC AND HETEROCYCLIC FUSED-RING QUINOLINECARBOXYLIC ACIDS USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | MAOB 4198/4885MAOA 4473/4885PRKCI 406/4885 |
| US-20230094341-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885PRKCI 889/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | MAOB 870/4885MAOA 1875/4885PRKCI 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.